Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

Completed · Phase 3

Conditions studied: Mucositis, Pain, Unspecified Adult Solid Tumor, Protocol Specific

In brief

This was an open-label, single-dose study to assess the safety, tolerability, and absorption/distribution kinetics of a single 100 µg dose of fentanyl sublingual spray in opioid-tolerant cancer subjects, with or without oral mucositis.

Key facts

Study ID

NCT00956254

Run by

INSYS Therapeutics Inc

People needed

18

Starts

2009-10-01

Expected to finish

2010-10-01

Last updated by the study team

2013-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• InSys Therapeutics, Incorporated — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.